Premium
Highly B lymphocyte‐specific tamoxifen inducible transgene expression of CreER T2 by using the LC‐1 locus BAC vector
Author(s) -
Boross Peter,
Breukel Cor,
van Loo Pieter Fokko,
van der Kaa Jos,
Claassens Jill W.,
Bujard Hermann,
Schönig Kai,
Verbeek J. Sjef
Publication year - 2009
Publication title -
genesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.093
H-Index - 110
eISSN - 1526-968X
pISSN - 1526-954X
DOI - 10.1002/dvg.20549
Subject(s) - cre recombinase , transgene , biology , microbiology and biotechnology , transgenesis , genetically modified mouse , gene targeting , gene , locus (genetics) , cre lox recombination , enhancer , conditional gene knockout , recombinase , tamoxifen , gene expression , genetics , phenotype , recombination , cancer , breast cancer , reproductive biology , embryogenesis
The generation of cell type specific inducible Cre transgenic mice is the most challenging and limiting part in the development of spatio‐temporally controlled knockout mouse models. Here we report the generation and characterization of a B lymphocyte‐specific tamoxifen‐inducible Cre transgenic mouse strain, LC‐1‐hCD19‐CreER T2 . We utilized the human CD19 promoter for expression of the tamoxifen‐inducible Cre recombinase (CreER T2 ) gene, embedded in genomic sequences previously reported to give minimal position effects after transgenesis. Cre recombinase activity was evaluated by cross‐breeding the LC‐1‐hCD19‐CreER T2 strain with a strain containing a floxed gene widely expressed in the hematopoietic system. Cre activity was only detected in the presence of tamoxifen and was restricted to B lymphocytes. The efficacy of recombination ranged from 27 to 61% in the hemizygous and homozygous mice, respectively. In conclusion, the LC‐1‐hCD19‐CreER T2 strain is a powerful tool to study gene function specifically in B lymphocytes at any chosen time point in the lifecycle of the mouse. genesis 47:729–735, 2009. © 2009 Wiley‐Liss, Inc.